Shandong Boan Biotechnology Co., Ltd. (6955.HK)

9.970 -0.010 (-0.10%) At close: 04:08PM HKT

Shandong Boan Biotechnology Co., Ltd.

No. 39 Keji Avenue
High-Tech Industrial Development Zone
Yantai
China
86 53 5437 9111
https://www.boan-bio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 813

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Hua Jiang	Executive Chairlady & CEO	3.81M	N/A	1978
Dr. Changlin Dou	COO, President of R&D and Executive Director	5.44M	N/A	1963
Mr. Shenghan Wang	Chief Financial Officer	N/A	N/A	1980
Mr. Jun Lu	Senior VP and Head of Biotechnology Engineering Center & Quality Department	N/A	N/A	1966
Mr. Deyong Song	Head of Biologics Discovery Department	N/A	N/A	1983
Ms. Chunna You	Senior Vice President of R&D Center	N/A	N/A	N/A
Mr. Zhou Ming	Chief Medical Officer	N/A	N/A	N/A
Ms. Siu Kuen Lai FCIS, FCS	Company Secretary	N/A	N/A	1976

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Shandong Boan Biotechnology Co., Ltd. develops, manufactures, and commercializes biologics in Mainland China and internationally. Its commercialized products include Boyounuo (BA1101) bevacizumab injection for the treatment of metastatic or recurrent non-small cell lung cancer (NSCLC), recurrent glioblastoma, epithelial ovarian, fallopian tube or primary peritoneal cancer, and cervical cancer; and Boyoubei BA6101, a human immunoglobulin G2 monoclonal antibody for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The company develops BA1102 denosumab injection to treat patients with skeletal-related events caused by multiple myeloma and bone metastases from solid tumors, as well as giant cell tumour of bone; BA5101 dulaglutide injection indicated for glycemic control in adults with type-2 diabetes; and BA9101 aflibercept intravitreous injection to treat neovascular wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinopathy of prematurity. It also develops BA1104 to treat patients with melanoma, NSCLC, malignant pleural mesothelioma, RCC, classical hodgkin lymphoma, SCCHN, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal and gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma; BA2101, a human monoclonal antibody that targets interleukin-4 receptor subunit alpha; BA1202, a CEA/CD3 bispecific antibody; BA1106, a non-IL-2 blocking anti-CD25 antibody; BA1301: an antibody drug conjugate (ADC) candidate that targets Claudin 18.2; BA1105, a recombinant anti-Claudin 18.2 fully human IgG1 monoclonal antibody; and BA1302, a novel CD228-directed ADC. The company was founded in 2013 and is headquartered in Yantai, China. Shandong Boan Biotechnology Co., Ltd. is a subsidiary of Shandong Luye Pharmaceutical Co., Ltd.

Corporate governance

Shandong Boan Biotechnology Co., Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.